The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Serious Eye Disease Gives Birth to Invention of Major New Eye Care Device

February 23, 2011 5:35 pm | by Bio-Medicine.Org | News | Comments

ORLANDO, Fla., Feb. 23, 2011 /- The Eye-POD-Eye-Care-Kit was created by a Doctor who suffered a serious eye malady, Bells-Palsy. Inventor Dr. Courtenay created the Eye ~ POD™ to answer his struggles with dry eyes, a side effect of Bells-Palsy. The affliction was caused by scratching...


New vaccine technology protects mice from hepatitis C virus

February 23, 2011 1:37 pm | by EurekAlert | News | Comments

(University of Copenhagen) HCV mutates so strongly that traditional vaccines are useless. However, University of Copenhagen researchers are the first to succeed in developing a vaccine, which provides future hope for medical protection from the hepatitis C virus.


Support the Have a HeArt Benefit, Feb. 25

February 23, 2011 12:35 pm | by Arizona State University | News | Comments

ASU's College of Nursing & Health Innovation is hosting a "Have a HeART Benefit," Feb. 25, with proceeds going to the College's NP Healthcare more


Review highlights need for more education and guidance on CAM use in midwifery

February 23, 2011 10:38 am | by EurekAlert | News | Comments

(Wiley-Blackwell) Complementary and alternative medicine is increasingly popular in maternity care, but health care professionals need formal evidence-based education and guidance about its use. University-based members of the Network of Researchers in the Public Health of...


ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software

February 23, 2011 10:36 am | by Bio-Medicine.Org | News | Comments

CLEVELAND, Feb. 23, 2011 /- ViewRay™, Inc., a privately held medical device company, has received U.S. FDA marketing clearance for its radiotherapy treatment planning and delivery software. The software is a critical component of the company's new radiation therapy system, which...


Extenze Tablets: Recall

February 23, 2011 10:31 am | by U.S. Food & Drug Administration | News | Comments

Counterfeit dietary supplement contains tadalafil, sildenafil, and/or sibutramine, which may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.


Synovis 1Q profit jumps on surgical product sales

February 23, 2011 9:45 am | by The Associated Press | News | Comments

Medical device maker Synovis Life Technologies Inc. said Wednesday its fiscal first-quarter profit nearly tripled on a boost in sales of its key surgical products.The company earned $1.8 million, or 16 cents per share, up from $643,000, or 6 cents per share, during the same period a year prior....

Neurocrine Biosciences to Present at Citi's 2011 Global Health Care Conference

February 23, 2011 9:34 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Feb. 23, 2011 /- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at Citi's 2011 Global Health Care Conference in New York.   The live presentation takes...


Dave Anderson and William Thomsen Join SRI International's Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery

February 23, 2011 9:34 am | by Bio-Medicine.Org | News | Comments

MENLO PARK, Calif., Feb. 23, 2011 /- SRI International, an independent nonprofit research and development organization, announced today that two new principal scientists, Dave Anderson, Ph.D., and William Thomsen, Ph.D., have joined its Center for Advanced Drug Research (CADRE) in...


Vertex sees positive data from Phase 3 CF study

February 23, 2011 9:33 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Vertex Pharmaceuticals Inc. of Cambridge today released results of a Phase 3 study of its VX-770 drug candidate for a specific type of cystic fibrosis (CF) that showed a relative mean improvement in lung function of about 17 percent over placebo.


Fluidnet finds $500K in debt funding

February 23, 2011 8:37 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Fluidnet Inc., an Amesbury-based maker of advanced intravenous systems, has raised $500,000 of a planned $2 million debt round, according to federal documents.

MIT nanoparticle discovery aimed at new vaccines

February 23, 2011 8:37 am | by Mass High Tech: The Journal of New England Technology | News | Comments

MIT researchers have discovered that new nanoparticles could lead to safe vaccines for HIV, malaria, cancer and other infectious diseases.

Novo Nordisk Submits First Recombinant Treatment for Factor XIII Deficiency for U.S. Regulatory Approval

February 23, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

PRINCETON, N.J., Feb. 23, 2011 /- Novo Nordisk announced today that a Biologic License Application (BLA) has been submitted to the U.S. Food and Drug Administration (FDA) requesting the approval of a recombinant factor XIII compound (rFXIII) for the vast majority of patients with...


Roche Teams with Womack Army Medical Center to Become First IVD Manufacturer approved for Remote Network Connectivity with DOD

February 23, 2011 8:33 am | by Bio-Medicine.Org | News | Comments

INDIANAPOLIS and FORT BRAGG, N.C., Feb. 23, 2011 /- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received approval from the U.S. Department of Defense (DOD) to provide remote service and support for its lab analyzers at Womack Army Medical Center through the DOD's secure...


Hospira MedNetâ„¢ Portal Safety Software Benchmarking System Debuts at HIMSS

February 23, 2011 6:36 am | by Bio-Medicine.Org | News | Comments

ORLANDO, Fla., Feb. 23, 2011 /- Hospira, Inc. (NYSE: HSP ), a leading provider of clinical information and medication delivery technologies, today announced the unveiling of the Hospira MedNet™ Portal at the Healthcare Information and Management Systems Society (HIMSS) Annual...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.